Arcadia Biosciences, Inc. (NASDAQ: RKDA) announced on January 12, 2026 that it has entered into definitive agreements to exercise certain outstanding preferred investment options, allowing the company to raise approximately $2.1 million in gross proceeds. The exercise involves up to 808,595 shares originally issued in December 2020, January 2021, August 2022 and March 2023, with an exercise price of $9.00 per share reduced to $2.575 per share. The transaction is expected to close on or about January 12, 2026, subject to customary closing conditions. The company plans to use the net proceeds for working capital and general corporate purposes, providing a short‑term liquidity boost amid its ongoing cash‑burn concerns.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.